Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
World game at war: why some European nations have threatened a World Cup boycott 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
LAWRENCE, Mass., April 16, 2018 -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.
Date: Wednesday, April 18, 2018
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
U.S. dial-in: 1-800-263-0877
TOLL/INTERNATIONAL dial-in: 1-323-794-2094
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.
The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2971422
Investor Relations Contact: Loraine V. Upham
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.
Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: [email protected]
www.bostonti.com
